Trade iBio, Inc. - IBIO CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.0133
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 0.767
• Open: 0.7791
• 1-Year Change: -5.51%
• Day's Range: 0.7554 - 0.7791

Trade iBio, Inc. - IBIO

iBio is a biopharmaceutical company behind the FastPharming System that helps with drug development “from concept to clinic”.

Headquartered in Texas, iBio was founded in 2008 and operates in biopharmaceuticals and bioprocessing segments along with its subsidiary, iBio CDMO LLC. 

iBio’s main product is the FastPharming System, which has helped produce monoclonal antibodies, subunit vaccines, cytokines and other recombinant proteins, according to the company’s site. 

iBio has also built the Glycaneering Development Services, which provides “greater control over the glycosylation of complex biopharmaceuticals''. 

The company operates in the fields of oncology, fibrotic and infectious diseases. 

The company’s development and manufacturing services deliver fast, scalable and sustainable solutions, enabling iBio to draw a licence agreement with Planet Biotechnology, and collaboration agreements with CC-Pharming Ltd, Safi BioSolutions and several other companies to develop therapeutic solutions.

The company went public in 2020 on the NYSE American. iBio, Inc. stock trades under the ticker symbol IBIO.

Check out the IBIO price history and today’s share value at Capital.com. Always stay on top of the latest price developments with our live IBIO stock chart.